SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Triangle Pharmaceuticals (VIRS)
VIRS 40.030.0%Oct 10 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thomas E. Wetherby who wrote (9)7/2/1997 11:00:00 AM
From: (no name provided)   of 34
 
True. AIDS drugs have been approved in 40 days. BUT it takes years to complete the trials. Check out how long the protease inhibitors and 3TC trials were. These are two to four year trials. VIRS' MKC442 is the latest stage drug and is in Phase I/II.

David Barry was on CNBC a couple of weeks ago and said not to expect any drugs on the market until 1999-2000.

By that time, VIRS will have run out of money several times over and will have to continue to do equity deals. This in turn will result in substantial dilution.

In addition, the markets will be extremely competitive at that point. Several new reverse transcriptase inhibitors will be out (Glaxo, Gilead) and at least one protease inhibitor (Glaxo/Vertex). Granted the market will be larger, but only smaller pieces of pie are left.

Therefore, I would contend that VIRS while its management is experienced and excellent is grossly overvalued. This is a early-stage biotech company with all the risks associated with clinical trials.

If you think a $500 million market cap is in line with other biotechs, then check out

1. NXCO - Approvable drug cap $300 million

2. SEQU, LIPO, NXTR - Approved drugs caps $300 million

3. GILD - Approved and late stage drugs $800 million (but they have $300 million in cash).

Kafka666
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext